Logo
x

Search

Subscribe Now

 Clinical Trial

PharmaShots Weekly Snapshots (December 16 – December 20, 2024)

PharmaShots Weekly Snapshots (December 16 – December 20, 2024)

  • December 20, 2024
Regeneron Reports Results from P-II (ROXI-VTE-I and ROXI-VTE-II) Trials of REGN7508 and REGN9933 for Venous Thromboembolism

Regeneron Reports Results from P-II (ROXI-VTE-I and ROXI-VTE-II) Trials of REGN7508 and REGN9933 for Venous Thromboembolism

  • December 20, 2024
Roche Reports the P-IIb (PADOVA) Trial Data of Prasinezumab for Early-Stage Parkinson’s Disease

Roche Reports the P-IIb (PADOVA) Trial Data of Prasinezumab for Early-Stage Parkinson’s Disease

  • December 20, 2024
Merck Discontinues Clinical Development Programs Evaluating Vibostolimab and Favezelimab for Various Indications

Merck Discontinues Clinical Development Programs Evaluating Vibostolimab and Favezelimab for Various Indications

  • December 19, 2024
Regeneron Reports Data from P-III (QUASAR) Trial of Eylea HD (Aflibercept) in Patients with Macular Edema following Retinal Vein Occlusion

Regeneron Reports Data from P-III (QUASAR) Trial of Eylea HD (Aflibercept) in Patients with Macular Edema following Retinal Vein O...

  • December 18, 2024
Viridian Therapeutics Reports Topline Data from P-III (THRIVE-2) Study of Veligrotug to Treat Chronic Thyroid Eye Disease

Viridian Therapeutics Reports Topline Data from P-III (THRIVE-2) Study of Veligrotug to Treat Chronic Thyroid Eye Disease

  • December 17, 2024
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.